- Home
- / Luyan Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Luyan Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥8.5
2024-10-29
Market Capitalization
¥3.3 B
2024-10-29
Revenue
¥20.3 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.5B | 15.0B | 15.5B | 17.5B | 19.4B | 19.7B | 20.3B |
| Cost of goods sold | 10.6B | 13.8B | 14.3B | 16.2B | 17.9B | 18.3B | 18.9B |
| Gross profit | 874.7M | 1.1B | 1.2B | 1.3B | 1.5B | 1.5B | 1.5B |
| Gross profit margin, % | 7.6% | 7.8% | 7.6% | 7.4% | 7.3% | ||
| Operating expense total | 452.2M | 567.8M | 581.8M | 646.6M | 679.5M | 695.4M | 717.6M |
| Depreciation and amortization | 36.6M | 56.2M | 66.0M | 59.5M | 56.2M | 61.0M | 73.1M |
| EBITDA | 422.4M | 569.2M | 618.2M | 685.4M | 793.4M | 770.0M | 754.5M |
| EBITDA margin, % | 3.8% | 4.0% | 3.9% | 3.9% | 3.7% | ||
| EBIT | 381.9M | 488.1M | 544.1M | 608.7M | 693.0M | 704.5M | 683.6M |
| EBIT margin, % | 3.3% | 3.5% | 3.5% | 3.6% | 3.4% | ||
| Interest income | 2.0M | 2.0M | 3.5M | 5.2M | 3.9M | 5.1M | 3.8M |
| Interest expense | 118.9M | 149.7M | 163.9M | 184.1M | 219.1M | 222.9M | 206.7M |
| Pre tax profit | 259.8M | 344.1M | 371.2M | 415.2M | 466.0M | 469.4M | 453.3M |
| Income tax expense | 75.2M | 86.6M | 104.3M | 110.6M | 115.0M | 104.9M | 105.6M |
| Net Income | 184.6M | 257.5M | 266.9M | 304.6M | 351.0M | 364.5M | 347.7M |